Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03710369 |
| Other study ID # |
H14-01736 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
November 1, 2015 |
| Est. completion date |
October 2, 2018 |
Study information
| Verified date |
October 2018 |
| Source |
University of British Columbia |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The degree to which endurance exercise performance is diminished in acute hypoxia is variable
and appears to be the result of several different physiological processes, however this
research focuses on hypoxic pulmonary vasoconstriction (HPV). Sildenafil, a pulmonary
vasodilator, has been used with mixed results to improve athletic performance in hypoxia.
Because sildenafil has been shown to reduce HPV in some individuals, we believe that its
effectiveness is closely related to the magnitude of the HPV response and the degree that
individual exercise performance declines in hypoxia. This research will investigate the
relationship between sildenafil, HPV, and exercise performance.
Description:
1. Purpose
The purpose of this research proposal is to evaluate the role of hypoxic pulmonary
vasoconstriction (HPV) and the formation of arteriovenous anastomoses (shunts) in
hypoxia and their effect on endurance exercise performance. The pulmonary vasodilator
sildenafil will be used to reverse the effects of HPV during exercise. Large
between-subject variability in exercise performance in hypoxia could be explained by
similar variability in the HPV response. Elite and recreational athletes could benefit
significantly from being aware of their HPV response to hypoxia and could alter their
training accordingly based on this knowledge. The vasodilator sildenafil may provide a
level playing field for those athletes who are compromised by a robust HPV response.
2. Hypothesis
A greater decline in exercise performance in acute moderate hypoxia (FIO2 = 0.16) will
be correlated with a higher pulmonary artery pressure (PAP) during steady-state exercise
and resting in hypoxia, increased arteriovenous anastomoses in hypoxia, and a lower
hypoxic ventilatory response (HVR). These subjects will have significantly improved
exercise performance in hypoxia with sildenafil administration. This increase in
performance will be associated with reduced PAP and increases in cardiac output.
3. Justification
Professional athletic competitions are frequently held at moderate altitude: 1500-2999
meters, or a barometric pressure (PB) of 635-525 mmHg. These competitions include sports
such as sky-running competitions and ski randonnée racing as well as Olympic
competitions, for example the 1968 Mexico City Olympics, held at an altitude of 2,240
meters.
Reasons for holding a competition at altitude vary. Some event host cities have venues
that are situated at moderate altitude. Winter events that require a significant
snowpack, such as Nordic and alpine ski races, are routinely held above 1500 meters.
Finally, some athletes such as track cyclists and long track speed skaters may seek out
moderate altitude venues where decreased atmospheric pressure reduces aerodynamic drag.
As elevation increases above sea level, PB decreases. While the fractional concentration
remains the same, this decrease reduces the partial pressures of the individual gases
that make up the ambient air (primarily: oxygen, nitrogen, carbon dioxide). Decreased PB
causes a reduction in the partial pressure of oxygen (PO2), resulting in less oxygen per
given volume of air (hypoxia). The effects of reduced PB and the resultant physiologic
effects of hypoxia on athletes are significant.
The human respiratory system responds to hypoxia with hypoxic pulmonary
vasoconstriction. In the lung, each alveolus is surrounded by a mesh-like network of
blood vessels (capillaries). An important concern in respiratory physiology is the
matching of blood flow to pulmonary ventilation, called the ventilation-perfusion (V/Q)
ratio. When V/Q mismatch occurs, oxygen transport from the airspace of the lung to the
tissues is disrupted. The HPV response acts to improve V/Q mismatch in hypoxia by
directing blood flow away from under-ventilated (hypoxic) lung units and towards lung
units that are receiving adequate ventilation. This is a useful response in the case of
local hypoxia, for example, if a patient inhales a foreign object that becomes lodged in
a bronchiole in the lung, airflow to the downstream lung units is impeded. The HPV
response directs blood flow away from the hypoxic lung units and towards the other,
better-ventilated parts of the lung where it can be properly oxygenated. This change in
blood flow occurs at the pre-capillary level where smooth muscles surrounding the
pulmonary arterioles constrict to close the vessels. This example of the HPV response to
local hypoxia is beneficial to overall gas exchange. In the case of global hypoxia, at
altitude, the HPV response may not be helpful and may in fact reduce oxygen transport.
In global hypoxia, where all lung units are hypoxic, the HPV response still occurs,
reducing blood flow throughout the lung even though the ideal response would be a global
increase in blood flow to maximise the ability to transport O2.
The result of the HPV response in global hypoxia is a marked increase in the pressure of
the pulmonary artery (PAP), further increased during moderate and intense exercise.
Increases in PAP lead to decreased stroke volume and cardiac output (Q). Because Qmax
cannot increase, at any given workload Q is a higher fraction of Qmax. When exercising
maximally, VO2max (a product of Q and the arterial content of oxygen (CaO2)) is also
reduced because Q cannot increase above Qmax to compensate for decreased CaO2.
When VO2max is reduced at altitude, metabolic rate at a given workload represents a
higher relative intensity (i.e. percentage of VO2max). This increased intensity required
for a certain workload is reflected in a reduced time to exhaustion at a constant work
rate or an increased time to completion for constant task events. During submaximal
exercise, when CaO2 is reduced, HR, ventilation, and Q are increased to maintain O2
delivery at a given intensity. The reduction in exercise economy is most notable in
endurance events. According to Fulco et al, events lasting less than two minutes are
essentially unaffected by altitude. Events greater than two minutes in duration see
significant increases in race completion times.
Hypoxia-induced pulmonary hypertension has also been associated with intra-pulmonary
arteriovenous anastomoses (shunts). It has been hypothesized that shunts act as a
release mechanism for increased PAP. In situations where pulmonary pressures are
increased pathologically, the shunts open, allowing blood to bypass pulmonary
circulation relieving pressure. It is also possible that shunts reduce the deleterious
effect of right ventricular (RV) afterload on Q (caused by increased PAP), and allow an
increase in Q. Several studies show that shunts are minimal to non-existent in most
humans at rest, but both exercise and hypoxia are significant stimuli to cause shunt
opening. Shunting appears to occur more frequently in some subjects in hypoxia while
others remain unaffected.
A strategy used to mitigate the performance decline at altitude is to lower PAP by
promoting pulmonary arteriole smooth muscle relaxation pharmaceutically.
Phosphodiesterase (PDE) inhibitors act on the nitric oxide (NO) system in smooth muscle
to reduce pulmonary artery pressure. The mechanism and effect of the PDE inhibitor
sildenafil will be examined as a performance enhancer in hypoxic exercise conditions.
Originally investigated as an anti-angina medication, sildenafil has been successfully
used to treat pulmonary arterial hypertension and erectile dysfunction because of its
vasodilatory properties on the NO pathway. Sildenafil is a PDE-5 inhibitor with a
similar molecular structure to cGMP. By competing with cGMP (cyclic guanosine
monophosphate) for binding sites on PDE-5, sildenafil prevents cGMP breakdown,
increasing the concentration available for smooth muscle relaxation. Sildenafil does not
increase smooth muscle relaxation by increasing NO availability, but by inhibiting the
mechanism that reduces the effects of NO.
In addition to its therapeutic use, sildenafil has recently been studied for its
potential to enhance exercise performance, specifically in hypoxia. Ghofrani et al. were
the first to report the effects of sildenafil on exercise performance in hypoxia and
found a significant improvement in exercise capacity. Ghofrani hypothesized that
sildenafil would improve hypoxic exercise tolerance by blunting the pulmonary
hypertensive response, decreasing PAP and thereby reducing RV afterload allowing an
increase in Q.
Subsequent studies have attempted to elucidate the mechanism through which sildenafil
might improve performance with mixed success. Because increases in mean power output
during a time-trial are directly related to performance outcomes, there is significant
potential for sildenafil to be used as an ergogenic aid in endurance sport. Despite the
logical rationale, the results of subsequent investigations into the ergogenic potential
of sildenafil have been inconsistent, some show a benefit in hypoxia and others show no
significant effect when compared to placebo.
Sildenafil is an effective pulmonary vasodilator in hypoxia, and does increase Q. In the
2006 study by Hsu et al, several subjects showed a significant improvement in time-trial
performance following sildenafil administration. These subjects also showed an
exaggerated decline in exercise performance in hypoxia. By grouping their subjects
according to those with a greater than or less than one minute improvement in time-trial
performance between placebo and sildenafil, the authors classified subjects as
responders and non-responders. The responders had higher pulmonary vascular resistance
(PVR) due to increased PAP and resultant increased RV afterload. In these subjects,
sildenafil improved performance by decreasing PAP and PVR, reducing RV afterload, and
improving V/Q mismatch. Non-responders had no such increases in PAP, PVR, or performance
after taking sildenafil. Kressler et al, acknowledge that responders as described by Hsu
may represent only a small fraction of the population and may not have been included in
the second study.
The differences in responders and non-responders could be explained by the
inter-individual variability in the HPV response. Some humans have a much more robust
HPV response where pulmonary blood flow is dramatically reduced, causing significant
decreases in PAP and Q. Others may have a nearly non-existent HPV response allowing
blood flow to remain relatively unchanged even during hypoxic exercise. Similarly, there
is high inter-individual variability in the exercise performance response to hypoxia.
Some athletes perform poorly at altitude, while others performance is relatively
unaffected. We believe that poor performance at altitude may be the result of a robust
HPV response and that sildenafil may act to equalize this, bringing those with a robust
HPV response to the same level as those with a minimal response.
4. Objectives
The objective of the first phase of the study is to evaluate the HPV response in
normoxia (with placebo), hypoxia (with placebo), and hypoxia (with sildenafil) using
both steady-state exercise and a time-trial race simulation. Cardiopulmonary variables
including pulse oxygen saturation (SPO2), heart rate (HR), ventilation, (VE), and oxygen
consumption (VO2) will be measured. During steady-state exercise, PAP and cardiac output
(Q) will be measured using the tricuspid jet method. During the time-trial, time to
completion and average power will be recorded.
The objective of the second phase of the study is to determine the magnitude of
responses in HPV, HVR, and shunt in various levels of hypoxia and if this response is
reduced with sildenafil.
5. Research Method
Participants: Ten healthy, male or female, competitive cyclists will be recruited to
participate in the study. Participants will be recruited using advertisements posted on
campus and distributed electronically to local cycling clubs. Participants must refrain from
the consumption of alcohol or caffeine, foods high in nitrates including beets and green
leafy vegetables, and abstain from vigorous exercise for 24 hours prior to each visit.
Familiarization: Subjects will report to the Environmental Physiology Laboratory (EPL) to
sign informed consent and be familiarized with the metabolic cart and hypoxic chamber. This
visit will take approximately 1 hour.
Pre-testing: Each subject will begin by completing a screening test including pulmonary
function testing (PFT) using spirometry to measure forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC). Subjects will perform a baseline, ramp VO2max test
using a stationary cycle ergometer and a metabolic cart. Work rate will start at 100 Watts
(W), and increase by 30 W/min until volitional exhaustion. Expired gases will be collected in
a mixing chamber to determine VO2max as an estimate of aerobic fitness. Fifteen minutes after
completing the normoxic test, the subject will complete a second, hypoxic (FIO2 = 0.16)
baseline ramp test. This visit will take approximately 1.5 hours. Following successful
admittance to the study, a second session will be scheduled.
Study Sessions (Phase 1): Once admitted to the study, subjects will report to the EPL on
three occasions for Phase 1 of the study, where they will complete one hypoxic (FIO2 = 0.16)
practice and three (randomized) experimental (one hypoxic control: FIO2 = 0.16 with placebo,
one hypoxic sildenafil: FIO2 = 0.16 with sildenafil, and one normoxic control: FIO2 = 0.21
with placebo) 15km time-trials. Each experimental trial will be separated by one week. One
hour prior to the time-trial, subjects will be given either 50mg sildenafil or placebo. After
an hour, a 4ml venous blood sample will be taken to test for serum sildenafil levels.
Subjects will be asked to complete a self-selected warm-up on the cycle ergometer as if they
are preparing for a race. Following warm-up, subjects will cycle for 15 minutes at a power
output corresponding to 50% of their peak power (determined in pre-testing) in normoxia or
hypoxia. Upon completion of the steady-state portion, subjects will be allowed to rest for 5
minutes before beginning their 15km time-trial. Throughout the exercise bout, expired gases
will be collected using a metabolic cart to measure cardiopulmonary parameters (SPO2, HR,
ventilation (VE) and VO2). During the steady-state portion, cardiac output will be measured
with Doppler echocardiography. Pulmonary artery pressure will be estimated by
echocardiography of the tricuspid jet performed by a trained sonographer. During time-trial
exercise, performance variables (time to completion and mean power output) will be recorded.
Each visit will take approximately 2.5 hours.
The experiment will utilize a randomized, double blind, crossover design. Participants will
complete the entire protocol after sildenafil once and placebo twice and researchers will be
blinded to the condition. A computerized random number generator will determine the order in
which the trials are completed. In both normoxic and hypoxic conditions, the subject will
breathe air supplied by the EPL hypoxic chamber. The chamber can be operated both at
simulated altitude and sea-level. By setting the chamber to ambient air conditions, the
subject is blinded to the condition as they are still breathing air from the chamber, which
is on and making the same noise and at the same humidity as if simulating altitude.
Data Analysis: During steady-state and the time-trial, mean SPO2, HR, VE, VO2, Q and PAP
during the final five minutes of the steady-state and the entire time trial will be compared
using analysis of variance (ANOVA) between sea-level placebo, hypoxic placebo, and hypoxic
sildenafil. The decrease in time-trial mean power output (Δ power) will be determined between
hypoxia and normoxia with placebo and will be compared to the increase in mean PAP (Δ PAP)
and decreased Q (Δ Q) by determining the correlation coefficient. Multivariate regression
analysis will be used to compare the dependent variables (SPO2, VO2, PAP, and Q) with the
effect of sildenafil on mean power output in hypoxia.
During steady-state exercise and time-trial in hypoxia, we expect to observe significant
decreases in SPO2, VO2, and Q, and significant increases in HR, VE, and PAP compared to
sea-level. We hypothesize that decreases in time-trial mean power output in hypoxia are the
result of (and thus will be negatively correlated with) increases in pulmonary artery
pressure and accompanied by a decrease in Q. We believe sildenafil will reduce PAP and
increase Q, allowing an increase in mean power output.
Study Sessions (Phase 2): Subjects will report to the EPL and sildenafil (50 mg) or placebo
will be administered (order of administration to be determined randomly by computer
assignment). One hour after ingesting the pill, a 4ml venous blood sample will be taken.
Subjects will be tested for intrapulmonary shunt and PAP will be measured during different
levels of hypoxia (FIO2= 0.21, 0.16, 0.12) corresponding to sea-level, 2500 meters, and 4500
meters. Shunt will be determined using the agitated saline contrast echocardiography
technique. Hypoxic gas will be generated using mixed O2 and N2 contained in a large mixing
chamber and delivered to the subject via tubing and a one-way non-rebreathing mask. The
procedure will be repeated with the remaining medication and no less than one week between
trials. Each visit will take approximately two hours.
The experiment will utilize a randomized, double blind, crossover design. Participants will
complete the entire protocol after taking sildenafil and placebo and researchers will be
blinded to the condition. A computerized random number generator will determine the order in
which the trials are completed. In both normoxic and hypoxic conditions, the subject will
breathe air from a large mixing chamber (balloon).
Data Analysis: A 3x2 analysis of variance (ANOVA) will be used to compare the effects of
hypoxia (sea-level, moderate hypoxia, and severe hypoxia) and medication (sildenafil and
placebo) on SPO2, VE, VO2, Q, and PAP at rest. A 3x2x2 ANOVA will be used to assess the
effects of hypoxia (sea-level, moderate hypoxia, and severe hypoxia), medication (sildenafil
and placebo), and presence of intrapulmonary shunt (present or not present) on PAP.
At rest, with increasing levels of hypoxia we expect increases in VE, VO2, and PAP and
decreases in SPO2, and Q. These changes will be reduced with sildenafil compared to placebo.
At any given level of hypoxia, subjects with intrapulmonary shunts present will exhibit a
higher PAP and lower SPO2. With sildenafil, fewer subjects will exhibit pulmonary shunting in
hypoxia and PAP will be decreased.
